Breaking News, Collaborations & Alliances

De Motu Cordis Expands DPI Partnership with Catalent

Announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

De Motu Cordis (DMC) unveiled plans for the next stage of development with its contract development and manufacturing organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion plans encompass services from drug product manufacturing and device assembly through to commercial launch of DMC’s product, DMC-IH1. DMC-IH1 is an inhaled epinephrine drug-device combination product being developed for the treatment of anaphylaxis using a dry ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters